{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXAMETHASONE&page=14", "query": { "intervention": "DEXAMETHASONE", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1868, "total_pages": 187, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXAMETHASONE&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXAMETHASONE&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T13:40:54.921Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01369121", "title": "Tolerability Study of Xerecept® in Pediatric Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain Edema", "Brain Tumor" ], "interventions": [ { "name": "XERECEPT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celtic Pharma Development Services", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 15, "start_date": "2010-06", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2013-07-30", "last_synced_at": "2026-10-24T13:40:54.921Z", "location_count": 2, "location_summary": "Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369121" }, { "nct_id": "NCT01553214", "title": "Improving White Blood Cell Collection From Healthy Donors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Allogeneic Granulocyte Donation" ], "interventions": [ { "name": "Filgrastim", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1000, "start_date": "2012-12-31", "completion_date": "2032-01-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-24T13:40:54.921Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01553214" }, { "nct_id": "NCT01946152", "title": "Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma-Light Chain Only", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Filgrastim-sndz", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2014-03-05", "completion_date": "2020-03-18", "has_results": true, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-10-24T13:40:54.921Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01946152" }, { "nct_id": "NCT07639723", "title": "Aprepitant to Improve Same Day Discharge for TKA", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "PONV" ], "interventions": [ { "name": "Aprepitant Injection", "type": "DRUG" }, { "name": "Ondansetron (Zofran)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Endeavor Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 350, "start_date": "2026-07", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-24T13:40:54.921Z", "location_count": 1, "location_summary": "Skokie, Illinois", "locations": [ { "city": "Skokie", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07639723" }, { "nct_id": "NCT00288080", "title": "Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "Oral antiandrogen", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "LHRH agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": 612, "start_date": "2005-12", "completion_date": "2022-05-20", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-10-24T13:40:54.921Z", "location_count": 245, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 194 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Auburn", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00288080" }, { "nct_id": "NCT03817320", "title": "PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ALL, Childhood", "Lymphoblastic Lymphoma, Childhood", "Lymphoblastic Leukemia, Acute, Childhood" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Asparaginase", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Methotrexate (IT)", "type": "DRUG" }, { "name": "Triple IT (Methotrexate, Hydrocortisone, Cytarabine)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 24, "start_date": "2019-02-12", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-10-24T13:40:54.921Z", "location_count": 17, "location_summary": "Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03817320" }, { "nct_id": "NCT04501614", "title": "A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)", "Ph+ Mixed Phenotype Acute Leukemia (MPAL)", "Philadelphia Chromosome-Like ALL (Ph-like ALL)" ], "interventions": [ { "name": "Ponatinib", "type": "DRUG" }, { "name": "Chemotherapy Agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 11, "start_date": "2021-02-24", "completion_date": "2024-07-19", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-10-24T13:40:54.921Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 10 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT04501614" }, { "nct_id": "NCT02732015", "title": "Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Sarcoma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Fosaprepitant Dimeglumine", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Rolapitant Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2016-10-12", "completion_date": "2020-07-10", "has_results": true, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-10-24T13:40:54.921Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02732015" }, { "nct_id": "NCT03906617", "title": "Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Robotic Lung Surgery" ], "interventions": [ { "name": "Intercostal nerve block and wound infiltration with liposomal bupivacaine", "type": "DRUG" }, { "name": "Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cooper Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 34, "start_date": "2019-04-10", "completion_date": "2022-06-10", "has_results": false, "last_update_posted_date": "2021-11-12", "last_synced_at": "2026-10-24T13:40:54.921Z", "location_count": 1, "location_summary": "Camden, New Jersey", "locations": [ { "city": "Camden", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03906617" }, { "nct_id": "NCT01455389", "title": "TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "DOTAP:Chol-TUSC2", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genprex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-02", "completion_date": "2020-09-28", "has_results": false, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-24T13:40:54.921Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01455389" } ] }